Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial-Reference-Cited by-同舟云学术

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Published:2021-02-18 Issue:3 Volume:27 Page:504-514
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Cascone Tina^ORCID,William William N.,Weissferdt Annikka,Leung Cheuk H.,Lin Heather Y.,Pataer Apar,Godoy Myrna C. B.,Carter Brett W.,Federico Lorenzo,Reuben Alexandre^ORCID,Khan Md Abdul Wadud^ORCID,Dejima Hitoshi^ORCID,Francisco-Cruz Alejandro,Parra Edwin R.^ORCID,Solis Luisa M.^ORCID,Fujimoto Junya,Tran Hai T.,Kalhor Neda,Fossella Frank V.,Mott Frank E.,Tsao Anne S.,Blumenschein George,Le Xiuning,Zhang Jianjun^ORCID,Skoulidis Ferdinandos,Kurie Jonathan M.,Altan Mehmet,Lu Charles,Glisson Bonnie S.,Byers Lauren Averett^ORCID,Elamin Yasir Y.,Mehran Reza J.,Rice David C.,Walsh Garrett L.,Hofstetter Wayne L.,Roth Jack A.^ORCID,Antonoff Mara B.,Kadara Humam,Haymaker Cara^ORCID,Bernatchez Chantale,Ajami Nadim J.,Jenq Robert R.,Sharma Padmanee^ORCID,Allison James P.,Futreal Andrew^ORCID,Wargo Jennifer A.^ORCID,Wistuba Ignacio I.,Swisher Stephen G.^ORCID,Lee J. Jack^ORCID,Gibbons Don L.^ORCID,Vaporciyan Ara A.,Heymach John V.^ORCID,Sepesi Boris

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-020-01224-2.pdf

Reference45 articles.

1. Martin, J. et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J. Clin. Oncol. 20, 1989–1995 (2002).

2. Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008).

3. Group, N. M.-A. C. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383, 1561–1571 (2014).

4. Pataer, A. et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol. 7, 825–832 (2012).

5. Hellmann, M. D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42–e50 (2014).

Cited by 351 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy;International Journal of Pharmaceutics;2024-03

2. Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-03

3. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer;Frontiers in Pharmacology;2024-02-05

4. Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements;International Journal of Clinical Oncology;2024-01-28

5. Gut microbiome for predicting immune checkpoint blockade-associated adverse events;Genome Medicine;2024-01-19